Online Database of Chemicals from Around the World 产品搜索 | 产品提交 | 产品推广 |

网站主页 >> 化工产品目录 >> 利纳西普>> 市场分析报告
 

利纳西普市场分析报告

Rilonacept (CAS 501081-76-1) Market Research Report 2021
BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS).

Global Market Report of Rilonacept (CAS 501081-76-1)
October 2016

Global Rilonacept Drugs Market Growth 2021-2026
... latest study, the 2021 growth of Rilonacept Drugs will have significant ... the most conservative estimates of global Rilonacept Drugs market size (most likely ... market shares, and growth opportunities of Rilonacept Drugs market by product type, application ...

CAS 501081-76-1 Rilonacept Chemical Report & Database
... listed. The substance covered (Rilonacept) are classified by the Chemical ... Report & Database definitions: Name: Rilonacept: Rilonacept Chemical Registry number: 769198057913 ... : Chemical or Reaction Intermediate The Rilonacept Report & Database gives Market ...

Regeneron Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
... has one marketed product: ARCALYST (rilonacept) Injection for Subcutaneous Use, which ... . Its late stage programs are rilonacept, which is being developed for the ...

Cryopyrin-associated Periodic Syndromes (CAPS) - Market Insights, Epidemiology, and Market Forecast - 2030
... effective in treating CAPS. Anakinra, rilonacept, and canakinumab are ... with CAPS. Arcalyst (Rilonacept): Regeneron Pharmaceuticals Rilonacept, formerly known as IL-1 TRAP ... key driver of inflammation in CAPS. Rilonacept is a dimeric fusion protein consisting ...

Pericarditis - Pipeline Insight, 2021
... releases. Pericarditis Emerging Drugs Rilonacept: Kiniska Pharmaceuticals Rilonacept is a recombinant fusion protein. It is currently ... R-Pharm International, LLC Key Products Rilonacept RPH-104

Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028
... of Recurrent Pericarditis in the coming years. Rilonacept (Kiniksa Pharmaceuticals, Ltd.) is the first ...

Interleukin 1 (IL1) - Pipeline Review, H1 2018
Interleukin 1 (IL1) - Pipeline Review, H1 2018 SUMMARY According to the recently published report 'Interleukin 1 (IL1) - Pipeline Review, H1 2018'; Interleukin 1 (IL1) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 ...

Interleukin 1 (IL1) - Pipeline Review, H2 2018
Interleukin 1 (IL1) - Pipeline Review, H2 2018 SUMMARY Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of ...

Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth
Global Orphan and Rare Dermatology Drugs Market to 2024 - An Increasingly Competitive Landscape as New Companies Enter the Market with Novel Products, Driving Strong Market Growth SUMMARY Dermatology is a highly diverse therapy area, in terms of severity ...

Scleroderma - Pipeline Insight, 2021
... Belimumab Abatacept CAM2043 Tofacitinib Sarilumab Rilonacept FCX 013 FCR001 VIB7734 AVID200 ...

REGENERON, Outperform - Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout
... , 2011 on REGN named “Is Trap Safer? Rilonacept vs. NVS’ Ilaris in Gout”.

Kiniksa Pharmaceuticals Ltd (KNSA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
... . Its pipeline product portfolio includes Rilonacept used for the treatment of recurrent ...




Copyright ©  chemBlink. 版权所有. 免责声明 | 网站简介 | 在线联系